Prevnar 13® & Prevnar 20™ Storage and Coding Fact Sheet

Prevnar 13®
Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM_{197} Protein)



Prevnar 20™
Pneumococcal 20-valent Conjugate Vaccine



How Supplied[1,2]

0.5 mL suspension for intramuscular injection, supplied in a single-dose prefilled syringe.

Storage and Handling[1,2]

Prevnar 13®	Prevnar 20™
After shipping, **Prevnar 13®** may arrive at temperatures between 2°C to 25°C (36°F to 77°F). Upon receipt, store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard if the vaccine has been frozen. Prevnar 13® is stable at temperatures up to 25°C (77°F) for 4 days. These data are not recommendations for shipping or storage, but may guide decisions for use in case of temporary temperature excursions.	After shipping, **Prevnar 20™** may arrive at temperatures between 2°C to 25°C (36°F to 77°F). Upon receipt, store refrigerated at 2°C to 8°C (36°F to 46°F). Syringes should be stored in the refrigerator horizontally to minimize the resuspension time. Do not freeze. Discard if the vaccine has been frozen. Prevnar 20™ should be administered as soon as possible after being removed from refrigeration. Prevnar 20™ can be administered provided total (cumulative multiple excursions) time out of refrigeration (at temperatures between 8°C and 25°C) does not exceed 96 hours. Cumulative multiple excursions between 0°C and 2°C are also permitted as long as the total time between 0°C and 2°C does not exceed 72 hours. These are not, however, recommendations for storage.

CPT Code[3]

Prevnar 13®	Prevnar 20™
90670 (Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use)	90677 (Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use)

CVX Code[4]

Prevnar 13®	Prevnar 20™
133	216

Billing Code for Diagnosis (ICD-10)

Prevnar 13®		Prevnar 20™	
Medicare	G0009 (Administration of pneumococcal vaccine)[3]	Medicare	G0009 (Administration of pneumococcal vaccine)[3]
Commercial	90471 (Immunization administration [includes percutaneous, intradermal, subcutaneous, or intramuscular injections]; 1 vaccine [single or combination vaccine/toxoid])[5]	Commercial	90471 (Immunization administration [includes percutaneous, intradermal, subcutaneous, or intramuscular injections]; 1 vaccine [single or combination vaccine/toxoid])[5]
	90460 (Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered)[5]		

NDC Numbers[1,2]

Prevnar 13®		Prevnar 20™	
0005-1971-02	Prefilled Syringe, 1 Dose (10 per package)	0005-2000-10	Prefilled Syringe, 1 Dose (10 per package)
0005-1971-05	Prefilled Syringe, 1 Dose (1 per package)	0005-2000-02	Prefilled Syringe, 1 Dose (1 per package)

CPT = Current Procedural Terminology, CVX = Codes for Vaccine Administered, NDC = National Drug Code.

Please see Indications and Important Safety Information on page 2. Please click for Prevnar 20™ and Prevnar 13® full Prescribing Information. Prevnar 20™ full Prescribing Information is also available at https://www.prevnar20hcp.com/. Prevnar 13® full Prescribing Information is also available at https://www1.pfizerpro.com/product/prevnar-13/adult

Pfizer

Prevnar 13® & Prevnar 20™ Storage and Coding Fact Sheet

Prevnar 13®
Pneumococcal 13-valent Conjugate Vaccine
(Diphtheria CRM_{197} Protein)



Prevnar 20™
Pneumococcal 20-valent
Conjugate Vaccine



Indications

- Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
- In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)

Limitations of Use and Effectiveness

- Prevnar 13® will only help protect against *S. pneumoniae* serotypes in the vaccine

- Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
- This indication for the prevention of pneumonia caused by *S. pneumoniae* serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial

Important Safety Information

- Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
- Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks
- In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
- In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
- In adults, the most common side effects were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash
- In children 6 years through 17 years of age, Prevnar 13® is administered as a single dose

- Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20™ or to diphtheria toxoid is a contraindication
- Safety and immunogenicity data on Prevnar 20™ are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20™
- In adults 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults 18 through 59 years of age

Please click for Prevnar 20™ and Prevnar 13® full Prescribing Information. Prevnar 20™ full Prescribing Information is also available at https://www.prevnar20hcp.com/. Prevnar 13® full Prescribing Information is also available at https://www1.pfizerpro.com/product/prevnar-13/adult

References: 1. Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM_{197} Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019. **2.** Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2021. **3.** Centers for Medicare & Medicaid Services (CMS). Billing and coding: Medicare preventive coverage for certain vaccines. Revised January 1, 2022. Accessed February 25, 2022. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=54767&DocID=A54767 **4.** Centers for Disease Control and Prevention. IIS: Current HL7 standard code set CVX – vaccines administered. Revised February 14, 2022. Accessed February 25, 2022. https://www2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=cvx **5.** American Medical Association. CPT categories/new vaccine codes (including incorporation of ACIP abbreviations listing) long descriptors. Updated February 1, 2022. Accessed March 2, 2022. https://www.ama-assn.org/system/files/covid-vaccine-long-descriptors.pdf

Marketed by Pfizer Inc.
Manufactured by Wyeth Pharmaceuticals LLC.